Protara Therapeutics IncTARA
Price$2.76

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$70MTTM through 30 Jun 2026
Free Cash Flow -$66.2MTTM through 30 Jun 2026

Margins

Current

Returns

-34.9%ROE
-33.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio15.69x
Net Debt-$135.8Mnet cash position
Cash & Equivalents$17.1M

Quality Metrics

Altman Z-Score5.58
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'14
FY2014: $2.9M
Diluted EPS-$1.36TTM
'21'22'23'24'25
FY2025: $-1.34

Dividend

No dividend

Capital Allocation

R&D Spend$53.2M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.